North American Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET- F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90)), by Application (Oncology, Cardiology) - Forecasts to 2020

  • ID: 3631673
  • Report
  • Region: North America, United States
  • 181 Pages
  • Markets and Markets
1 of 5
North American Nuclear Medicine Market Expected to Reach USD 2.98 Billion in 2020 From USD 1.97 Billion in 2015, Growing at a CAGR of 8.6%.

FEATURED COMPANIES

  • Bayer Healthcare
  • Bracco Imaging S.P.A
  • Cardinal Health, Inc.
  • GE Healthcare
  • IBA Molecular Imaging
  • Mallinckrodt PLC
  • MORE
The North American nuclear medicine/radiopharmaceuticals market is poised to reach USD 2.98 billion by 2020 from USD 1.97 billion in 2015, growing at a CAGR of 8.6% during the forecast period of 2015 to 2020.

Nuclear medicine is a specialized field of medicine that covers all aspects of the use of radioactive substances, through either injection or ingestion, for the diagnosis or treatment of diseases such as cancer, cardiovascular disease, and neurological diseases. The nuclear medicine/radiopharmaceuticals market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, whereas radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.

In 2015, the diagnostic segment accounted for the largest share of the North American nuclear medicine/radiopharmaceuticals market, by type. Moreover, the SPECT segment is expected to account for the largest share of the North American diagnostic nuclear medicine/radiopharmaceuticals market. This can be attributed to growing cancer patient population, increasing preference for SPECT procedures, advances in SPECT radioisotopes, and cyclotron-based Tc-99m generation. In addition, in 2015, the beta emitters segment is expected to account for the largest share of the North American therapeutic nuclear medicine/radiopharmaceuticals market, owing to heavy funding for research on beta emitters, new therapeutic radioisotopes, and reimbursement policies in favor of using radiopharmaceuticals for cancer therapy.

In 2015, the cardiology application accounts for the largest share of North American nuclear medicine/radiopharmaceuticals market for SPECT applications. This large share can be attributed to new hardware and software designs in SPECT, rising incidence rate of CVDs, and adoption of SPECT in new cardiac applications. The PET market is dominated by oncology applications owing to its accuracy, and preference of PET over conventional imaging. In 2015, the therapeutic market is dominated by thyroid applications. This large share of thyroid applications can be attributed to the factors such as non-invasive method for treatment, and growing incidence of thyroid cancer.

In 2015, U.S. is expected to account for the largest share of the North American nuclear medicine/radiopharmaceuticals market, followed by Canada. The U.S. market is also likely to witness the highest growth rate of the North American nuclear medicine/radiopharmaceuticals market in the coming years. The U.S.’s large share and high growth rate can be attributed to the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (agreements, collaborations, contracts, and partnerships, marketing and promotions, new product launches, expansions, acquisitions, funding and grants, patent coverage extensions, website launches, and license renewals) to increase their market shares and establish a strong foothold in the North American market.

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of top players in the North American nuclear medicine/radiopharmaceuticals market. The report analyzes the North American nuclear medicine/radiopharmaceuticals, by type of isotopes, applications, and country
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the North American nuclear medicine/radiopharmaceuticals market
- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine products, applications, and technologies across countries
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the North American nuclear medicine/radiopharmaceuticals market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the North American nuclear medicine/radiopharmaceuticals market
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Bayer Healthcare
  • Bracco Imaging S.P.A
  • Cardinal Health, Inc.
  • GE Healthcare
  • IBA Molecular Imaging
  • Mallinckrodt PLC
  • MORE
1 Introduction
1.1 Objectives of Study
1.2 North American Radiopharmaceuticals Market Definition
1.3 North American Radiopharmaceuticals Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.2.1 Key Industry Insights
2.2.2.2 Key Data From Primary Sources
2.2.2.3 Key Insights From Primary Sources
2.3 North American Radiopharmaceuticals Market Size Estimation Methodology
2.4 Research Design
2.5 North American Radiopharmaceuticals Market Data Validation and Triangulation
2.6 Assumptions for the Study

3 Executive Summary
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook

4 Premium Insights
4.1 North American Nuclear Medicine Market
4.2 North American Nuclear Medicine Diagnostic Market, By Therapeutic and Spect Application
4.3 North American Nuclear Medicine Market, By Country
4.4 North American Nuclear Medicine Market, By Type (2015 vs 2020)

5 Market Overview
5.1 Introduction
5.2 North American Radiopharmaceuticals Market Segmentation
5.3 North American Radiopharmaceuticals Market Dynamics
5.3.1 Drivers
5.3.1.1 Increasing Preference for Spect and PET Scans
5.3.1.2 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment
5.3.1.3 Advances in Radiotracers
5.3.1.4 Growing Incidence of Cancer and Cvds
5.3.1.5 Rising Awareness About the Effective Use of Radiopharmaceuticals in Various Applications
5.3.2 Restraints
5.3.2.1 Requirement of High Capital Investments to Limit the Procurement of Scanners
5.3.2.2 Shorter Half-Life of Radiopharmaceuticals
5.3.2.3 Stringent Regulatory Guidelines and Good Manufacturing Practices
5.3.2.4 Competition From Conventional Diagnostic Procedures
5.3.3 Opportunities
5.3.3.1 Upcoming Radioisotopes
5.3.3.2 Alternative Diagnostic Radiopharmaceutical Solutions
5.3.3.3 Cyclotron-Based Production
5.3.3.4 Use of Radiopharmaceuticals in Neurological Applications
5.3.4 Challenges
5.3.4.1 Shutdown of Nuclear Reactors to Impact Production of Radioisotopes

6 North American Nuclear Medicine Market: Pipeline Assessment
6.1 Introduction
6.2 Diagnostic Radioisotopes
6.3 Therapeutic Radioisotopes

7 North American Nuclear Medicine Market, By Type
7.1 Introduction
7.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals
7.2.1 Spect Radiopharmaceuticals
7.2.1.1 Technetium-99m
7.2.1.2 Thallium-201
7.2.1.3 Gallium-67
7.2.1.4 Iodine-123
7.2.1.5 Other Spect Isotopes
7.2.2 PET Radiopharmaceuticals
7.2.2.1 Fluorine-18
7.2.2.2 Rubidium-82
7.2.2.3 Other PET Isotopes
7.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
7.3.1 Beta Emitters
7.3.1.1 Iodine-131
7.3.1.2 Yttrium-90
7.3.1.3 Samarium-153
7.3.1.4 Rhenium-186
7.3.1.5 Lutetium-177
7.3.1.6 Other Beta Emitter Isotopes
7.3.2 Alpha Emitters
7.3.2.1 Radium-223
7.3.3 Brachytherapy
7.3.3.1 Iodine-125
7.3.3.2 Iridium-192
7.3.3.3 Palladium-103
7.3.3.4 Cesium-131
7.3.3.5 Other Brachytherapy Isotopes

8 North American Nuclear Medicine Market, By Application
8.1 Introduction
8.2 Diagnostic Applications
8.2.1 Spect Applications
8.2.1.1 Cardiology
8.2.1.2 Lymphoma
8.2.1.3 Neurology
8.2.1.4 Thyroid
8.2.1.5 Other Spect Applications
8.2.2 PET Applications
8.2.2.1 Oncology
8.2.2.2 Cardiology
8.2.2.3 Neurology
8.2.2.4 Other PET Applications
8.3 Therapeutic Applications
8.3.1 Thyroid
8.3.2 Bone Metastasis
8.3.3 Lymphoma
8.3.4 Endocrine Tumors
8.3.5 Other Therapeutic Applications

9 North American Nuclear Medicine Market for Procedural Volume
9.1 Introduction
9.2 Diagnostic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
9.2.1 Spect Radiopharmaceuticals
9.2.2 PET Radiopharmaceuticals
9.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume
9.3.1 Beta Emitters
9.3.2 Brachytherapy

10 North American Nuclear Medicine Market, By Country
10.1 Introduction
10.2 Diagnostic Market
10.2.1 North America
10.2.1.1 U.S.
10.2.1.1.1 Domestic Production of Mo-99 in the U.S.
10.2.1.1.2 Approval of New Radiopharmaceuticals By Fda
10.2.1.2 Canada
10.2.1.2.1 Extension of Operations at the Canadian National Research Universal (NRU) Reactor
10.2.1.2.2 Alternative Medical Isotope Technologies in Canada
10.3 Therapeutic Market
10.3.1 North America
10.3.1.1 U.S.
10.3.1.1.1 Fda Approval for Alpha Emitter
10.3.1.1.2 Therapeutic Nuclear Medicine - Alternative Treatment Choice in Oncology
10.3.1.1.3 Growing Incidence of Thyroid Cancer
10.3.1.2 Canada
10.3.1.2.1 Expertise in Isotope Production
10.3.1.2.2 Government Initiatives to Increase the Number of Nuclear Medicine Treatment Centers
10.3.1.2.3 High Incidence of Cancer

11 Competitive Landscape
11.1 Overview
11.2 Competitive Situation and Trends
11.2.1 Introduction
11.2.2 Agreements, Collaborations, Contracts, and Partnerships
11.2.3 Marketing and Promotions
11.2.4 New Product Launches
11.2.5 Expansions
11.2.6 Acquisitions
11.2.7 Other Strategies
11.3 North American Nuclear Medicine Market: Empirical Assessment of Growth Strategies
11.3.1 Route to Strategic Growth: Organic and Inorganic Growth Strategies
11.3.2 Organic Growth Strategies
11.3.3 Inorganic Growth Strategies

12 Company Profiles
(Overview, Financials, Products & Services, Strategy, & Developments)*
12.1 Introduction
12.2 Cardinal Health, Inc.
12.3 Mallinckrodt PLC
12.4 GE Healthcare
12.5 Lantheus Medical Imaging, Inc.
12.6 Bayer Healthcare
12.7 Bracco Imaging S.P.A
12.8 Eczacibasi-Monrol Nuclear Products
12.9 Nordion, Inc.
12.10 Advanced Accelerator Applications S.A.
12.11 IBA Molecular Imaging

*Details on Financials, Product & Services, Strategy, & Developments Might Not Be Captured in Case of Unlisted Companies.

13 Appendix
13.1 Discussion Guide
13.2 Available Customizations
13.3 Knowledge Store: Marketsandmarkets’ Subscription Portal
13.4 Introducing RT: Real-Time Market Intelligence
13.5 Related Reports

List of Tables

Table 1 Alpha Radioimmunotherapy-Based Targeted Cancer Treatment Driving Market Growth
Table 2 Requirement of High Capital Investments and Short Half-Life of Radiopharmaceuticals Restraining Market Growth
Table 3 Potential Radioisotopes in the Pipeline to Offer Significant Growth Opportunities to Market Players
Table 4 Shutdown of Nuclear Reactors is A Major Challenge in This Market
Table 5 Details of Radiopharmaceuticals for Upcoming Diagnostic Applications
Table 6 Details of Radiopharmaceuticals for Upcoming Therapeutic Applications
Table 7 North American Nuclear Medicine Market Size, By Type, 2013-2020 (USD Million)
Table 8 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 9 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 10 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 11 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 12 North America: Technetium-99m Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 13 North America: Thallium-201 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 14 North America: Gallium-67 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 15 North America: Iodine-123 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 16 North America: Other Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 17 North America: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 18 North America: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 19 North America: Fluorine-18 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 20 North America: Rubidium-82 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 21 North America: Other PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 22 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 23 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 24 North America: Beta Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 25 North America: Beta Emitter Nuclear Medicine Market Size, By Isotope, 2013-2020 (USD Million)
Table 26 North America: Iodine-131 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 27 North America: Yttrium-90 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 28 North America: Samarium-153 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 29 North American Rhenium-186 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 30 North America: Lutetium-177 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 31 North America: Other Beta Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 32 North America: Alpha Emitter Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 33 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 34 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Isotope, 2013-2020 (USD Million)
Table 35 North America: Iodine-125 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 36 North America: Iridium-192 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 37 North America: Palladium-103 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 38 North America: Cesium-131 Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 39 North America: Other Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Country, 2013-2020 (USD Million)
Table 40 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Size for Spect Isotopes, By Country, 2013-2020 (USD Million)
Table 41 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Size for Spect Isotopes, By Type, 2013-2020 (USD Million)
Table 42 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Cardiology Spect Applications, By Country, 2013-2020 (USD Million)
Table 43 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Lymphoma Spect Applications, By Country, 2013-2020 (USD Million)
Table 44 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Neurology Spect Applications, By Country, 2013-2020 (USD Million)
Table 45 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Thyroid Spect Applications, By Country, 2013-2020 (USD Million)
Table 46 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Other Spect Applications, By Country, 2013-2020 (USD Million)
Table 47 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Country, 2013-2020 (USD Million)
Table 48 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for PET Applications, By Type, 2013-2020 (USD Million)
Table 49 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Oncology PET Applications, By Country, 2013-2020 (USD Million)
Table 50 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Cardiology PET Applications, By Country, 2013-2020 (USD Million)
Table 51 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Neurology PET Applications, By Country, 2013-2020 (USD Million)
Table 52 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size for Other PET Applications, By Country, 2013-2020 (USD Million)
Table 53 North American Nuclear Medicine Market Size for Therapeutic Applications, By Country, 2013-2020 (USD Million)
Table 54 North American Nuclear Medicine Market Size for Therapeutic Applications, By Type, 2013-2020 (USD Million)
Table 55 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Thyroid Applications, By Country, 2013-2020 (USD Million)
Table 56 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Bone Metastasis, By Country, 2013-2020 (USD Million)
Table 57 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Lymphoma, By Country, 2013-2020 (USD Million)
Table 58 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size for Endocrine Applications, By Country, 2013-2020 (USD Million)
Table 59 North American Nuclear Medicine Market Size for Other Therapeutic Applications, By Country, 2013-2020 (USD Million)
Table 60 North American Nuclear Medicine Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 61 North American Nuclear Medicine Market for Procedural Volume, By Country, 2013-2020 (Thousand Units)
Table 62 North America: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 63 North America: Spect Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 64 North America: PET Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 65 North America: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 66 North America: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 67 North America: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market for Procedural Volume, By Type, 2013-2020 (Thousand Units)
Table 68 North American Nuclear Medicine Market Size, By Type, 2013-2020 (USD Million)
Table 69 U.S.: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 70 U.S.: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 71 U.S.: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 72 U.S.: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 73 U.S.: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 74 Canada: Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 75 Canada: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 76 Canada: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 77 Canada: Spect Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 78 Canada: PET Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 79 U.S.: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 80 U.S.: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 81 U.S.: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 82 U.S.: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 83 Canada: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 84 Canada: Beta Emitters Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 85 Canada: Brachytherapy Nuclear Medicine/Radiopharmaceuticals Market Size, By Type, 2013-2020 (USD Million)
Table 86 Canada: Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Size, By Application, 2013-2020 (USD Million)
Table 87 Agreements, Collaborations, Contracts, and Partnerships, 2013-2016
Table 88 Marketing and Promotions, 2013-2016
Table 89 New Product Launches, 2013-2016
Table 90 Expansions, 2013-2014
Table 91 Acquisitions, 2013-2016
Table 92 Other Strategies, 2013-2016

List of Figures

Figure 1 North American Radiopharmaceuticals Market Segmentation
Figure 2 North American Radiopharmaceuticals Market: Research Methodology Steps
Figure 3 Key Data From Secondary Sources
Figure 4 Break Down of Primary Interviews: By Company Type, Designation, and Country
Figure 5 North American Radiopharmaceuticals Market Size Estimation Methodology: Bottom-Up Approach
Figure 6 North American Radiopharmaceuticals Market Size Estimation Methodology: Top-Down Approach
Figure 7 Research Design
Figure 8 Data Triangulation Methodology
Figure 9 Therapeutics Market to Witness the Highest Growth Rate From 2015 to 2020
Figure 10 North American Nuclear Medicine Therapeutics Market Share, By Type, 2015 vs 2020
Figure 11 Geographical Snapshot of the North American Nuclear Medicine Market, 2015
Figure 12 North American Nuclear Medicine Spect Applications Market Size, 2015 vs 2020 (USD Million)
Figure 13 Advances in Radiotracers to Propel Market Growth
Figure 14 Thyroid Application Segment Dominates the North American Therapeutic Nuclear Medicine Market in 2015
Figure 15 U.S. to Witness the Highest Growth Rate During the Forecast Period
Figure 16 Diagnostics Segment to Command the Largest Market Share During the Forecast Period
Figure 17 North American Nuclear Medicine Market Segmentation
Figure 18 North American Nuclear Medicine Market: Drivers, Restraints, Opportunities, & Challenges
Figure 19 Clinical Trials for Diagnostic & Therapeutic Radioisotopes, By Phase
Figure 20 Clinical Trials for Diagnostic & Therapeutic Radioisotopes, By Company & Institute
Figure 21 Clinical Trials for Radioisotopes, By Type
Figure 22 Clinical Trials for Diagnostic Radioisotopes, By Subtype
Figure 23 Clinical Trials for Diagnostic Radioisotopes, By Indication
Figure 24 Clinical Trials for Diagnostic Radioisotopes, By Phase
Figure 25 Clinical Trials for Diagnostic Radioisotopes, By Company & Institute
Figure 26 Clinical Trials for Therapeutic Radioisotopes, By Subtype
Figure 27 Clinical Trials for Therapeutic Radioisotopes, By Indication
Figure 28 Clinical Trials for Therapeutic Radioisotopes, By Phase
Figure 29 Clinical Trials for Therapeutic Radioisotopes, By Company & Institute
Figure 30 North American Nuclear Medicine Market Segmentation, By Type
Figure 31 Therapeutic Segment to Grow at the Highest CAGR of 10.0%
Figure 32 PET Segment to Grow at the Highest CAGR of 11.3% During the Forecast Period
Figure 33 Alpha Emitters Segment to Grow at the Highest CAGR of 16.8% During the Forecast Period
Figure 34 North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market Segmentation
Figure 35 Segmentation of North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market for Spect Isotopes
Figure 36 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 37 Neurology Application Segment to Grow at the Highest CAGR of 7.8% During the Forecast Period
Figure 38 Segmentation of North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Applications Market for PET Isotopes
Figure 39 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 40 Neurology Application Segment to Grow at the Highest CAGR of 12.6% During the Forecast Period
Figure 41 North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Applications Market Segmentation
Figure 42 U.S. to Grow at the Highest CAGR During the Forecast Period
Figure 43 Endocrine Tumors Application Segment to Grow at the Highest CAGR of 10.8% During the Forecast Period
Figure 44 U.S. to Command the Largest Share of the North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Market in 2015
Figure 45 North American Diagnostic Nuclear Medicine/Radiopharmaceuticals Market Overview
Figure 46 U.S. to Command the Largest Share of the North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Market in 2015
Figure 47 North American Therapeutic Nuclear Medicine/Radiopharmaceuticals Market Overview
Figure 48 Top 5 Strategies Adopted By Players Over the Last Three Years (2013-2016)
Figure 49 Battle for Market Share: Agreements, Collaborations, Contracts, and Partnerships Was the Key Strategy (2013 -2016)
Figure 50 Organic & Inorganic Growth Strategies: Industry Trend vs Key Players
Figure 51 Organic Growth Strategies, By Key Player (2013-2016)
Figure 52 Inorganic Growth Strategies, By Key Player (2013-2016)
Figure 53 Product Mix of the Key Players in the Market
Figure 54 Cardinal Health, Inc.: Company Snapshot
Figure 55 Mallinckrodt PLC: Company Snapshot
Figure 56 GE Healthcare: Company Snapshot
Figure 57 Lantheus Medical Imaging, Inc.: Company Snapshot
Figure 58 Bayer Healthcare: Company Snapshot
Figure 59 Nordion, Inc.: Company Snapshot
Figure 60 Advanced Accelerator Applications S.A.: Company Snapshot
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
5 of 5
- Advanced Accelerator Applications S.A.
- Bayer Healthcare
- Bracco Imaging S.P.A
- Cardinal Health, Inc.
- Eczacibasi-Monrol Nuclear Products
- GE Healthcare
- IBA Molecular Imaging
- Lantheus Medical Imaging, Inc.
- Mallinckrodt PLC
- Nordion, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll